Susan L. Baldwin

Center for Global Infectious Disease Research, Seattle Children's Research Institute

Affiliated withSeattle Children's Research Institute

Research Area

Biography

Susan L. Baldwin has not added Biography.
If you are Susan L. Baldwin and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant. ImmunoHorizons\| PubMed ID: 40285479	2025
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PloS one\| PubMed ID: 33705411	2021
Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Scientific reports\| PubMed ID: 33907221	2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. bioRxiv : the preprint server for biology\| PubMed ID: 34230930	2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. Journal of immunological methods\| PubMed ID: 34599915	2021
It Takes a Village: The Multifaceted Immune Response to Infection and Vaccine-Induced Immunity. Frontiers in immunology\| PubMed ID: 35359957	2022
: It's Complex. Microorganisms\| PubMed ID: 35889173	2022
Therapeutic efficacy against using ID93 and liposomal adjuvant formulations. Frontiers in microbiology\| PubMed ID: 36090093	2022
Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 36375278	2022
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 36586154	2023
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases\| PubMed ID: 36963657	2023
SARS-CoV-2 infection and immune responses. AIMS microbiology\| PubMed ID: 37091818	2023
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Infectious diseases and therapy\| PubMed ID: 37166567	2023
Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration. Pharmaceuticals (Basel, Switzerland)\| PubMed ID: 37242512	2023
Protective interplay: diminishes SARS-CoV-2 severity through innate immune priming. Frontiers in immunology\| PubMed ID: 38966641	2024
Antibodies as key mediators of protection against . Frontiers in immunology\| PubMed ID: 39286260	2024
The chosen few: isolates for IMPAc-TB. Frontiers in immunology\| PubMed ID: 39530100	2024
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent. mSphere\| PubMed ID: 39651886	2025
Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals. Frontiers in immunology\| PubMed ID: 39717773	2024
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques. npj antimicrobials and resistance\| PubMed ID: 39843983	2024